Donatello Salvatore
Potenza, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study.
Journal: Journal of clinical medicine
Published: February 16, 2026
Real-life effectiveness and safety of lumacaftor/ivacaftor in preschool children with cystic fibrosis: data from an italian multicentre study.
Journal: Pediatric research
Published: December 03, 2025
Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study.
Journal: International journal of molecular sciences
Published: October 10, 2025
Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis: A Review of Registry-Based Evidence.
Journal: Journal of clinical medicine
Published: April 29, 2025
Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study.
Journal: Therapeutic advances in respiratory disease
Published: February 11, 2025
Treatment decision-making for using CFTR modulator therapy in patients with cystic fibrosis.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: January 23, 2025
Real-world effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients with Phe508del -gating and -residual function genotypes.
Journal: Respiratory medicine
Published: December 08, 2024
Critical Issues in the Management of CRMS/CFSPID Children: A National Real-World Survey.
Journal: Pediatric pulmonology
Published: September 12, 2024
Corrigendum to "Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 years with Cystic Fibrosis and at Least one F508dek Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor". J Pediatr. 2024 Jun 28; 274:114176.
Journal: The Journal of pediatrics
Published: August 28, 2024
Italian Cystic Fibrosis Registry (ICFR). Report 2021-2022
Journal: Epidemiologia e prevenzione
Published: May 14, 2024
Nutritional Trends in Cystic Fibrosis: Insights from the Italian Cystic Fibrosis Patient Registry.
Journal: Journal of clinical medicine
Published: April 09, 2024
Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor.
Journal: The Journal of pediatrics
Published: January 29, 2024
Last Updated: 09/26/2026